The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer.
Breast cancer
Estrogen
Menarche
Menopause
Parity
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
17 Aug 2021
17 Aug 2021
Historique:
received:
13
06
2021
accepted:
02
08
2021
entrez:
24
2
2022
pubmed:
25
2
2022
medline:
25
2
2022
Statut:
epublish
Résumé
Menstrual and parity history might impact the risk for breast cancer. Data on the impact of these factors on other tumor characteristics are limited. A single center retrospective cohort study comprising all women with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, early breast cancer whose tumors were sent to OncotypeDX analysis. The prespecified subgroups were investigated: age of menarche (< 12 vs. ≥ 12 years), number of deliveries (0 vs. ≥ 1 childbirth and ≥ 5 childbirth vs. other), age of first delivery (≥ 30 years vs. younger age) and postmenopausal compared to premenopausal. The impact of age of menopause was also assessed categorically, using early (< 45 years) and late age of menopause (> 55 years). Differences in tumor characteristics were evaluated using T-test or Mann Whitney for continuous variables or Fisher's exact test for categorical variables. Outcomes were assessed by Kaplan-Meier survival analysis, with the log-rank test. A total of 620 women were included. After median follow-up of 10.4 years, early menopause was associated with significantly worse disease-free survival (HR = 2.26, p = 0.004) and overall-survival (HR = 2.60, p = 0.004), and multiparity was associated with significant worse disease-free survival (HR = 2.16, p = 0.026). These differences remain significant in multivariate analyses. Post-menopausal women were more likely to have stronger ER intensity (p = 0.002) but progesterone receptor (PR) positivity was less frequent (p = 0.009(. Early age of menarche was associated with PR positivity (p = 0.039). No other associations were found between the evaluated subgroups and tumor characteristics. The impact of endogenous estrogen exposure had little effect on breast cancer characteristics of early stage, luminal disease. Early menopause and multiparity were associated with worse outcome.
Sections du résumé
BACKGROUND
BACKGROUND
Menstrual and parity history might impact the risk for breast cancer. Data on the impact of these factors on other tumor characteristics are limited.
METHODS
METHODS
A single center retrospective cohort study comprising all women with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative, early breast cancer whose tumors were sent to OncotypeDX analysis. The prespecified subgroups were investigated: age of menarche (< 12 vs. ≥ 12 years), number of deliveries (0 vs. ≥ 1 childbirth and ≥ 5 childbirth vs. other), age of first delivery (≥ 30 years vs. younger age) and postmenopausal compared to premenopausal. The impact of age of menopause was also assessed categorically, using early (< 45 years) and late age of menopause (> 55 years). Differences in tumor characteristics were evaluated using T-test or Mann Whitney for continuous variables or Fisher's exact test for categorical variables. Outcomes were assessed by Kaplan-Meier survival analysis, with the log-rank test.
RESULTS
RESULTS
A total of 620 women were included. After median follow-up of 10.4 years, early menopause was associated with significantly worse disease-free survival (HR = 2.26, p = 0.004) and overall-survival (HR = 2.60, p = 0.004), and multiparity was associated with significant worse disease-free survival (HR = 2.16, p = 0.026). These differences remain significant in multivariate analyses. Post-menopausal women were more likely to have stronger ER intensity (p = 0.002) but progesterone receptor (PR) positivity was less frequent (p = 0.009(. Early age of menarche was associated with PR positivity (p = 0.039). No other associations were found between the evaluated subgroups and tumor characteristics.
CONCLUSIONS
CONCLUSIONS
The impact of endogenous estrogen exposure had little effect on breast cancer characteristics of early stage, luminal disease. Early menopause and multiparity were associated with worse outcome.
Identifiants
pubmed: 35201434
doi: 10.1007/s12672-021-00420-x
pii: 10.1007/s12672-021-00420-x
pmc: PMC8777527
doi:
Types de publication
Journal Article
Langues
eng
Pagination
26Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 2019 Nov 20;37(33):3152-3165
pubmed: 31479306
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):60-7
pubmed: 26545404
N Engl J Med. 2015 Jan 29;372(5):436-46
pubmed: 25495490
Am J Epidemiol. 2000 Apr 1;151(7):703-14
pubmed: 10752798
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
J Clin Oncol. 2017 Aug 10;35(23):2647-2655
pubmed: 28398846
JAMA. 2001 Feb 21;285(7):885-92
pubmed: 11180731
Am J Epidemiol. 1997 Aug 15;146(4):307-14
pubmed: 9270409
J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309
pubmed: 21743022
Int J Health Serv. 1993;23(2):373-86
pubmed: 8500953
JAMA Oncol. 2018 Nov 1;4(11):e181771
pubmed: 29931120
J Epidemiol Community Health. 1981 Sep;35(3):197-9
pubmed: 7328379
Lancet Oncol. 2015 Mar;16(3):266-73
pubmed: 25637340
Br J Cancer. 2005 Jan 17;92(1):167-75
pubmed: 15597097
Breast Cancer Res Treat. 2019 Jun;175(3):531-545
pubmed: 30929116
J Natl Cancer Inst. 2002 Apr 17;94(8):606-16
pubmed: 11959894
Am J Epidemiol. 1994 Apr 15;139(8):819-35
pubmed: 8178795
N Engl J Med. 2016 Aug 25;375(8):717-29
pubmed: 27557300
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 1983 Dec 1;309(22):1343-7
pubmed: 6633596
Breast Cancer Res Treat. 2012 Jul;134(2):769-81
pubmed: 22562122
Med Princ Pract. 2015;24(1):70-4
pubmed: 25402350
Int J Cancer. 2013 Jun 1;132(11):2619-29
pubmed: 23090881
J Natl Cancer Inst. 2011 Apr 6;103(7):562-70
pubmed: 21330633
Lancet Oncol. 2012 Nov;13(11):1141-51
pubmed: 23084519
J Natl Cancer Inst. 2003 Aug 20;95(16):1218-26
pubmed: 12928347
N Engl J Med. 2001 Jan 25;344(4):276-85
pubmed: 11172156
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Heart. 2018 Jul;104(13):1069-1075
pubmed: 29335253
Circulation. 2018 May 15;137(20):2166-2178
pubmed: 29760227
J Clin Oncol. 2021 Feb 20;39(6):557-564
pubmed: 33306425
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
Ann Intern Med. 2019 Jan 1;170(1):22-30
pubmed: 30534999
Breast Cancer Res Treat. 2006 Jun;97(3):245-54
pubmed: 16331345
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Cancer Treat Rev. 2016 Sep;49:65-76
pubmed: 27529149
Breast Cancer Res Treat. 2013 Jun;139(2):539-52
pubmed: 23674192
J Natl Cancer Inst. 2004 Dec 15;96(24):1856-65
pubmed: 15601642
Nat Rev Endocrinol. 2017 Jun;13(6):352-364
pubmed: 28304393
J Am Heart Assoc. 2017 Nov 2;6(11):
pubmed: 29097389
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922781
J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
pubmed: 21191117
J Natl Cancer Inst. 2014 Apr 28;106(5):
pubmed: 24777111
Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11):
pubmed: 29117982
Eur J Surg Oncol. 2017 May;43(5):921-930
pubmed: 28087099
Front Oncol. 2020 Aug 14;10:1470
pubmed: 32923400
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Horm Metab Res. 2016 Aug;48(8):489-96
pubmed: 27392117